ResearchMoz added Latest Research Report titled " DS5565 (Neuropathic Pain) - Forecast and Market Analysis to 2022 " to it's Large Report database.
Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=198421
DS-5565 is an oral, small-molecule analgesic being developed by Daiichi Sankyo for the treatment of PDN. It is a voltage-dependent calcium channel alpha-2-delta ligand, meaning that it has a mechanism of action similar to Lyrica and gabapentin, and reduces pain through the inhibition of calcium channel-associated currents. These compounds bind to the a-2-d subunits (a-2-d-1 and a-2-d-2) of voltage-dependent calcium channels, where the a-2-d-1 subunit is the main target for the analgesic effect of a-2-d ligands, while the a-2-d-2 subunit is thought to contribute to the CNS side effects of a-2-d ligands, although this has not been fully demonstrated (Yokoyama et al., 2013).
Scope
Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=198421
DS-5565 is an oral, small-molecule analgesic being developed by Daiichi Sankyo for the treatment of PDN. It is a voltage-dependent calcium channel alpha-2-delta ligand, meaning that it has a mechanism of action similar to Lyrica and gabapentin, and reduces pain through the inhibition of calcium channel-associated currents. These compounds bind to the a-2-d subunits (a-2-d-1 and a-2-d-2) of voltage-dependent calcium channels, where the a-2-d-1 subunit is the main target for the analgesic effect of a-2-d ligands, while the a-2-d-2 subunit is thought to contribute to the CNS side effects of a-2-d ligands, although this has not been fully demonstrated (Yokoyama et al., 2013).
Scope
- Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on DS-5565 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for DS-5565 for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of content
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
3 Disease Overview 12
3.1 Clinical Manifestations of Neuropathic Pain - Signs and Symptoms 14
3.1.1 Painful Diabetic Neuropathy 16
3.1.2 Postherpetic Neuralgia 17
3.1.3 Trigeminal Neuralgia 17
3.2 Etiology and Pathophysiology 18
3.2.1 Etiology 19
3.2.2 Pathophysiology 20
4 Disease Management 28
4.1 Diagnosis and Treatment Overview 28
4.1.1 Diagnosis 28
4.1.2 Treatment Overview and Guidelines 35
5 Competitive Assessment 45
5.1 Overview 45
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Table of content
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
3 Disease Overview 12
3.1 Clinical Manifestations of Neuropathic Pain - Signs and Symptoms 14
3.1.1 Painful Diabetic Neuropathy 16
3.1.2 Postherpetic Neuralgia 17
3.1.3 Trigeminal Neuralgia 17
3.2 Etiology and Pathophysiology 18
3.2.1 Etiology 19
3.2.2 Pathophysiology 20
4 Disease Management 28
4.1 Diagnosis and Treatment Overview 28
4.1.1 Diagnosis 28
4.1.2 Treatment Overview and Guidelines 35
5 Competitive Assessment 45
5.1 Overview 45
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
No comments:
Post a Comment